While the underlying mechanism remains speculative, this case underscores the need for clinician awareness of a possible hepatic side effect, particularly when encountering unexplained hyperbilirubinemia in patients receiving G-CSF, and the potential risk when prescribing G-CSF in patients with preexisting liver conditions. Here, CSF3 is linked to Hyperbilirubinemia.